Federal University of Latin American Integration | ClinicalTrials HQ

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Oral and Topical Phytocannabinoids for Psoriasis	Chemically-Induced Disorders, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, cannabis dependence, psoriasis, psychiatric disorder, skin disorder, substance-related disorder	Active, not recruiting	Phase 2	2026-09-24		NCT07839455
Cannabidiol Oil for Treatment-Resistant Major Depression	Depressive Disorder, Treatment-Resistant, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder	Recruiting	Phase 1 / Phase 2	2026-07-10		NCT07696871
EFFECTS OF A FULL SPECTRUM CANNABIS EXTRACT WITH DIFFERENT DOSES OF CBD AND THC ON THE MODULATION OF FIBROMYALGIA: A PILOT, MULTICENTER, OPEN LABEL CLINICAL TRIAL (FRIDINHA)	Neurobehavioral Manifestations, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, agnosia, fibromyalgia, muscle tissue disorder, musculoskeletal system disorder, nervous system disorder, neuromuscular disease, perceptual disorders, rheumatic disorder	Active, not recruiting	Phase 1 / Phase 2	2026-03-27		NCT07498023
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression	depressive disorder, mood disorder, psychiatric disorder	Recruiting	Phase 1 / Phase 2	2026-03-27		NCT06898606
Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase	Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy	Active, not recruiting	Phase 1 / Phase 2	2025-08-12		NCT07091747